📊 NIKA Key Takeaways
Is NIKA a Good Investment? Thesis Analysis
NIKA Pharmaceuticals exhibits terminal financial distress with zero revenue, negative stockholders equity of -$297.6K indicating technical insolvency, and only $1.9K cash reserves against $318.6K liabilities. The company's unsustainable cash burn rate of -$79.7K annually combined with severe liquidity constraints (current ratio 0.07x) indicates imminent operational failure.
Why Buy NIKA? Key Strengths
- Company maintains minimal operational footprint reducing ongoing cash burn relative to active pharmaceutical operations
- Still reporting to SEC, indicating continuation through formal restructuring processes possible
NIKA Investment Risks to Consider
- Negative stockholders equity of -$297.6K indicates technical insolvency and high bankruptcy risk
- Severe liquidity crisis with current ratio of 0.07x and only $1.9K cash against material liabilities
- Zero revenue generation with no demonstrated product commercialization or path to profitability
- Liabilities exceed total assets by 15x, creating structural insolvency
- Unsustainable cash burn of approximately -$79.7K annually with insufficient resources for continuation
Key Metrics to Watch
- Monthly cash depletion rate and timeline to complete liquidity failure
- Any revenue generation or clinical trial advancement announcements
- Bankruptcy filing, debt restructuring, or capital raise announcements
NIKA Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NIKA Profitability Ratios
NIKA vs Healthcare Sector
How NIKA PHARMACEUTICALS, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NIKA Overvalued or Undervalued?
Based on fundamental analysis, NIKA PHARMACEUTICALS, INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NIKA Balance Sheet & Liquidity
NIKA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NIKA PHARMACEUTICALS, INC's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
NIKA Growth Metrics (YoY)
NIKA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $156 | -$27.8K | $0.00 |
| Q3 2023 | N/A | -$6.3K | N/A |
| Q2 2023 | N/A | -$6.3K | N/A |
| Q1 2023 | N/A | $6.3K | N/A |
| Q3 2022 | N/A | $2.7K | $0.00 |
| Q2 2022 | N/A | $3.0K | $0.00 |
| Q1 2022 | N/A | -$5.8K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NIKA Capital Allocation
NIKA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NIKA PHARMACEUTICALS, INC (CIK: 0001145604)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NIKA
What is the AI rating for NIKA?
NIKA PHARMACEUTICALS, INC (NIKA) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NIKA's key strengths?
Claude: Company maintains minimal operational footprint reducing ongoing cash burn relative to active pharmaceutical operations. Still reporting to SEC, indicating continuation through formal restructuring processes possible.
What are the risks of investing in NIKA?
Claude: Negative stockholders equity of -$297.6K indicates technical insolvency and high bankruptcy risk. Severe liquidity crisis with current ratio of 0.07x and only $1.9K cash against material liabilities.
What is NIKA's revenue and growth?
NIKA PHARMACEUTICALS, INC reported revenue of $0.0.
Does NIKA pay dividends?
NIKA PHARMACEUTICALS, INC does not currently pay dividends.
Where can I find NIKA SEC filings?
Official SEC filings for NIKA PHARMACEUTICALS, INC (CIK: 0001145604) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NIKA's EPS?
NIKA PHARMACEUTICALS, INC has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NIKA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NIKA PHARMACEUTICALS, INC has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NIKA stock overvalued or undervalued?
Valuation metrics for NIKA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NIKA stock in 2026?
Our dual AI analysis gives NIKA PHARMACEUTICALS, INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NIKA's free cash flow?
NIKA PHARMACEUTICALS, INC's operating cash flow is $-79.7K, with capital expenditures of N/A.
How does NIKA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 2).